# An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

> **NCT01816659** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** Metformin ER

## Key facts

- **NCT ID:** NCT01816659
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2015-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01816659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01816659, "An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01816659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*